Understanding survival and factors affecting squamous cell carcinoma of the nasal vestibule
Survival and Prognostic Factors of Squamous Cell Carcinoma of the Nasal Vestibule: a Multi-centre Study
This study looks at how well people with squamous cell carcinoma of the nasal vestibule do after surgery and what factors might affect their survival.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istituto Clinico Humanitas Academic / other |
| Locations | 6 sites (Toulouse, Touluse and 5 other locations) |
| Trial ID | NCT05693116 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the survival rates and prognostic factors in patients who have undergone surgical treatment for primary squamous cell carcinoma of the nasal vestibule. It will collect data on patient demographics, tumor characteristics, and surgical details, and will analyze these factors to determine their influence on overall survival, disease-specific survival, and disease-free survival. Participants will be followed for a minimum of 6 months post-surgery, with the goal of potentially developing a new staging system to improve upon existing classifications.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with squamous cell carcinoma of the nasal vestibule who have undergone surgical treatment with curative intent.
Not a fit: Patients with recurrent disease or tumors originating from other sites that involve the nasal vestibule will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments and treatment strategies for patients with nasal vestibule carcinoma.
How similar studies have performed: While there may be existing studies on squamous cell carcinoma, this specific focus on nasal vestibule carcinoma and its prognostic factors is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of squamous cell carcinoma of the nasal vestibule * underwent upfront surgical treatment with curative intent * availability of clinical and radiological data for cT reassessment * availability of histological samples for pT reassessment * follow-up of at least 6 months after surgery. Exclusion Criteria: * patients initially referred for disease persistence or recurrence * patients affected by tumour involving the nasal vestibule but originating from other sites (eg. nasal cavities, skin of the nasal pyramid or upper lip)
Where this trial is running
Toulouse, Touluse and 5 other locations
- Centre Hospitalier Universitaire de Toulouse — Toulouse, Touluse, France (Recruiting)
- Humanitas Research Hospital — Rozzano, Milan, Italy (Recruiting)
- Cagliari University Hospital — Cagliari, Italy (Recruiting)
- IRCCS San Raffaele Hospital — Milan, Italy (Recruiting)
- Varese University Hospital — Varese, Italy (Recruiting)
- Sheffield Teaching Hospital NHS Foundation Trust — Sheffield, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Fabio Ferreli, MD — Humanitas Research Hospital IRCCS, Rozzano-Milan
- Study coordinator: Francesca Pirola, MD
- Email: francesca.pirola@humanitas.it
- Phone: 00390282243557
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.